Evidence map›Paper›PMID 42708038›Full record

Trial reportTheranostics2026

PEGylated IL2 and tumor-targeted radiotherapy augment CD8

Won Jong Jin, Hari Menon, Amber Bates, Lauren Zebertavage, Yujuan Wang, Paul A Clark, Alexander A Pieper, Caroline P Kerr, Tracy J Berg, Jens C Eickhoff and 13 more

Abstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Theranostics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Won Jong JinUniversity of Wisconsin Madison, Department of Human Oncology, Madison, WI, USA.
Hari MenonUniversity of Wisconsin Madison, Department of Human Oncology, Madison, WI, USA.
Amber BatesUniversity of Wisconsin Madison, Department of Human Oncology, Madison, WI, USA.
Lauren ZebertavageUniversity of Wisconsin Madison, Department of Human Oncology, Madison, WI, USA.
Yujuan WangUniversity of Wisconsin Madison, Department of Human Oncology, Madison, WI, USA.
Paul A ClarkUniversity of Wisconsin Madison, Department of Human Oncology, Madison, WI, USA.
Alexander A PieperUniversity of Wisconsin Madison, Department of Human Oncology, Madison, WI, USA.
Caroline P KerrUniversity of Wisconsin Madison, Department of Human Oncology, Madison, WI, USA.
Tracy J BergUniversity of Wisconsin Madison, Department of Human Oncology, Madison, WI, USA.
Jens C EickhoffUniversity of Wisconsin Madison, Department of Biostatistics and Medical Informatics, Madison, WI, USA.
Sarah SeiterUniversity of Wisconsin Madison, Department of Human Oncology, Madison, WI, USA.
A Mario Q MarcondesNektar Therapeutics, San Francisco, CA, USA.
Mary A TagliaferriNektar Therapeutics, San Francisco, CA, USA.
Willem W OverwijkNektar Therapeutics, San Francisco, CA, USA.
Tabassum A KennedyUniversity of Wisconsin Madison, Department of Radiology, Madison, WI, USA.
Paul M SondelUniversity of Wisconsin Madison, Department of Human Oncology, Madison, WI, USA.
Paul M HarariUniversity of Wisconsin Madison, Department of Human Oncology, Madison, WI, USA.
Justine Y BruceUniversity of Wisconsin Madison, Department of Medicine University of Wisconsin School of Medicine and Public Health.
Adam R BurrUniversity of Wisconsin Madison, Department of Human Oncology, Madison, WI, USA.
Reinier HernandezUniversity of Wisconsin Madison, Department of Medical Physics; Madison, WI, USA.
Irene M OngUniversity of Wisconsin Madison, Department of Biostatistics and Medical Informatics, Madison, WI, USA.
Jamey WeichertUniversity of Wisconsin Madison, Department of Radiology, Madison, WI, USA.
Zachary S MorrisUniversity of Wisconsin Madison, Department of Human Oncology, Madison, WI, USA.

Funding

UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Justine Yang Bruce · 1985 to 2026
$142.6M
Project 3: Modulation of the head and neck tumor immune microenvironment by targeting the TAM family of receptorsP50CA278595 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI David J Beebe · 2022 to 2026
$12.5M
Radionuclide Production and Radiochemistry Core Description CoreP01CA250972 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI MORRIS, ZACHARY SCOTT, WEICHERT, JAMEY P · 2020 to 2024
$12.5M
Project 4: Role of Receptor Tyrosine Kinase AXL in HNSCC Therapy ResistanceP50DE026787 · NIDCR · UNIVERSITY OF WISCONSIN-MADISON · PI HARARI, PAUL M · 2016 to 2020
$10.8M
Integrated Training For Physician-ScientistsT32GM140935 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI Anna Huttenlocher, Jeniel E Nett · 2021 to 2026
$6.5M
Immunomodulation of the Tumor Microenvironment with Molecular Targeted Radiotherapy to Facilitate an Adaptive Anti-Tumor Immune Response to Combined Modality ImmunotherapiesU01CA233102 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI MORRIS, ZACHARY SCOTT, WEICHERT, JAMEY P · 2018 to 2022
$4.0M
UW SPECT/CT AcquisitionS10OD028670 · OD · UNIVERSITY OF WISCONSIN-MADISON · PI WEICHERT, JAMEY P · 2020 to 2020
$598k
Targeted radionuclide therapy for tumor immunomodulation and enhancing immunotherapy responseF30CA268780 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI KERR, CAROLINE PAULA ANNE · 2022 to 2025
$145k
NCI NIH HHS F30 CA268780NCI NIH HHS P01 CA250972NCI NIH HHS P30 CA014520NCI NIH HHS P50 CA278595NCI NIH HHS U01 CA233102NIDCR NIH HHS P50 DE026787NIGMS NIH HHS T32 GM140935NIH HHS S10 OD028670
6 · The paper itself

Abstract

Combination of immune checkpoint inhibitors (ICI) with either radiotherapy or PEGylated interleukin 2 (pegIL2) has produced limited or no benefits over ICI alone in clinical trials. A triple combination of radiotherapy, pegIL2, and ICI may overcome the limitations of dual treatments. We report a phase II clinical trial evaluating tumor-targeted radiotherapy, pegIL2 (BEMPEG), and ICI (pembrolizumab) in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), and combination pre-clinically of radiopharmaceutical therapy (RPT), pegIL2, and ICI in HNSCC. Methods: Patients received one cycle of pegIL2 (0.006 mg/kg) plus pembrolizumab (200 mg) followed by external beam radiotherapy (EBRT), then two cycles of pegIL2 plus pembrolizumab. Adverse events, objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and immune response from peripheral blood mononuclear cells (PBMCs) and biopsies were evaluated. RPT ( Results: We report ORR of 40%, PFS of 4.2 months, OS of 13.6 months, and increased effector:regulatory T-cell ratios and memory CD8 Conclusions: Preclinically, tumor-targeted RPT and pegIL2 augment response to ICI through CD8

Indexed as

CD8-Positive T-LymphocytesHead and Neck NeoplasmsImmune Checkpoint InhibitorsInterleukin-2Polyethylene GlycolsSquamous Cell Carcinoma of Head and NeckAdultAgedAnimalsAntibodies, Monoclonal, HumanizedCombined Modality TherapyFemaleHumansMaleMiddle AgedAntibodies, Monoclonal, HumanizedImmune Checkpoint InhibitorsInterleukin-2pembrolizumabPolyethylene Glycolsanti-PD-1memory CD8+ T cellPD-L1+monocytePEGylated IL2radiation

Identifiers

PMID42708038
PMCPMC13549225

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.